IgA Nephropathy market set to grow 18.6% CAGR to 2036 with novel therapies and rising prevalence

The IgA Nephropathy (IgAN) market is projected to grow at a CAGR of 18.6% through 2036, driven by rising disease prevalence, improved diagnostics, and innovative therapies. New treatments like VOYXACT, TARPEYO, and FILSPARI, along with late-stage candidates from Novartis, Vertex, Biogen, and others, are reshaping disease management by targeting underlying causes rather than just symptoms. Strong R&D investment and clinical trials support this expansion, offering hope for better outcomes in chronic kidney disease linked to IgAN. Market value was USD 1.5 billion in 2025 and is expected to rise significantly with upcoming drug launches and increased awareness.